Please try another search
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. The company is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
Name | Age | Since | Title |
---|---|---|---|
Megan Baldwin | 49 | 2021 | Independent & Non-Executive Director |
David Jerimiah McAuliffe | 57 | 2019 | Non-Executive Chairman |
David Colin Wheeler | 65 | 2023 | Non-Executive Director |
Thomas Duthy | - | 2020 | Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review